Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation
Screening for bone fracture risk should be routine for over-40s with HIV, new guidelines recommend
HIV/HCV co-infection associated with increased risk of osteoporosis and fractures
HIV increases fracture risk, say Danes
High prevalence of osteoporosis and osteopenia in young men with HIV
HIV-positive people not on antiretrovirals are prone to inflammation-related bone loss
New tenofovir formulation works equally well with less effect on kidneys and bones
Low baseline CD4 cell count associated with greater bone loss after starting HIV therapy
Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss
